NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease

International Journal of Molecular Sciences

Elisa De Carlo¹  Alessandro Del Conte¹  Alessandra Bearz¹  Elisa Bertoli²  Anna Michelotti²  Marco de Scordilli² 

[1] Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Department of Medical Oncology, 33081 Aviano, Italy;Department of Medicine (DAME), University of Udine, 33100 Udine, Italy;

关键词: NSCLC;    MET;    RET;    NTRK;    KRAS;    HER2;   

DOI  :  10.3390/ijms23126748

来源: DOAJ

【 摘 要 】

Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a revolutionary change in the therapeutic scenario. The identification of oncogenic driver mutations in EGFR, ALK and ROS1 rearrangements identified a subset of patients who largely benefit from targeted agents. However, since the proportion of patients with druggable alterations represents a minority, the discovery of new potential driver mutations is still an urgent clinical need. We provide a comprehensive review of the emerging molecular targets in NSCLC and their applications in the advanced setting.

【 授权许可】

Unknown